5-[4-[(3S)-3-aminopyrrolidin-1-yl]-5-(4,5-difluoro-1H-benzimidazol-2-yl)-3-pyridinyl]-2-fluorobenzonitrile
C23H17F3N6 — CID 139392794
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[4-[(3S)-3-aminopyrrolidin-1-yl]-5-(4,5-difluoro-1H-benzimidazol-2-yl)-3-pyridinyl]-2-fluorobenzonitrile
5-[4-[(3S)-3-aminopyrrolidin-1-yl]-5-(4,5-difluoro-1H-benzimidazol-2-yl)-3-pyridinyl]-2-fluorobenzonitrile (PubChem CID 139392794) has the molecular formula C23H17F3N6 and a molecular weight of 434.43 g/mol. Its IUPAC name is 5-[4-[(3S)-3-aminopyrrolidin-1-yl]-5-(4,5-difluoro-1H-benzimidazol-2-yl)-3-pyridinyl]-2-fluorobenzonitrile.
Molecular Properties
| Compound Name | 5-[4-[(3S)-3-aminopyrrolidin-1-yl]-5-(4,5-difluoro-1H-benzimidazol-2-yl)-3-pyridinyl]-2-fluorobenzonitrile |
|---|---|
| PubChem CID | 139392794 |
| Molecular Formula | C23H17F3N6 |
| Molecular Weight | 434.43 g/mol |
| Exact Mass | 434.15 |
| IUPAC Name | 5-[4-[(3S)-3-aminopyrrolidin-1-yl]-5-(4,5-difluoro-1H-benzimidazol-2-yl)-3-pyridinyl]-2-fluorobenzonitrile |
| SMILES | N#Cc1cc(-c2cncc(-c3nc4c(F)c(F)ccc4[nH]3)c2N2CC[C@H](N)C2)ccc1F |
| InChI | InChI=1S/C23H17F3N6/c24-17-2-1-12(7-13(17)8-27)15-9-29-10-16(22(15)32-6-5-14(28)11-32)23-30-19-4-3-18(25)20(26)21(19)31-23/h1-4,7,9-10,14H,5-6,11,28H2,(H,30,31)/t14-/m0/s1 |
| InChIKey | KBDIPWWMSATCEK-AWEZNQCLSA-N |
| XLogP | 4.12 |
| TPSA | 94.62 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 434.43 |
| LogP ≤ 5 | 4.12 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 139392794 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.